HVH Precision Analytics and Diligentia Strategy Announce Upcoming Presentation at the 2020 American
New research on the use of claims data for gene therapy trials will be presented by HVH Precision Analytics and Diligentia Strategy...
Planning for a New Era: Commercial Strategy under the Lens of Public Scrutiny
In 2019, 44% of novel drugs approved in the U.S were classified with orphan designation. 60% of approved drugs fell into one or more...
Meet with us at the 38th annual J.P. Morgan Healthcare Conference, January 13-16, 2020
If you are attending the J.P. Morgan Healthcare Conference and would like to learn about how Diligentia can support your commercial...
Meet with us at the RARE Patient Advocacy Summit, September 18-20, 2019
If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email...
Meet with us at the 37th annual J.P. Morgan Healthcare Conference, January 6-9, 2019
If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email...
Meet with us at the 8th annual World Orphan Drug Congress in Washington, D.C., April 25-27, 2018
If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email...
Meet with us at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco January 8-11, 201
If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email...
Diligentia President, Joff Masukawa, will serve as a panelist at the Virginia Bioscience Commerciali
Joff Masukawa, Diligentia Strategy, will be the featured speaker at the November 3rd Virginia Bioscience Commercialization Luncheon. He...
Diligentia President, Joff Masukawa, will serve as a panelist in this evening's Johns Hopkins Un
Other panelists include Kevin D. Frick, M. Gregg Bloche, Jeff Kahn, and Brett McCone.
What Does the Government Investigation on the Orphan Drug Program Mean for Drug Manufacturers?
Sen. Tom Cotton, R-Ark., is one of three GOP senators seeking an investigation into six-figure annual costs for drugs intended to treat...
